Over time, Aifa has approved diverse experiments to verify the effectiveness of drugs already in use even in the presence of Covid-19: we are talking about tocilizumab, a monoclonal antibody that blocks the production of interleukin-6, hydroxychloroquine, colchicine, azithromycin, ivermectin and plasma therapy, based on sampling of antibodies from convalescent patients. The latter, however, did not give the desired results. Its effectiveness is not satisfactory